However, the clinical application of TRAIL therapy has been limited by its inherently short half-life in blood (3–5 min in rodents and 24–31 min in non-human primates), insufficient delivery to the targets, and the appearance of cancer cell populations with intrinsic or acquired resistance to TRAIL-mediated programmed cell death [13, 14]. This evidence concerns the gene TNFSF10 and cancer.